Bernard Charbonnel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bernard Charbonnel has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Annpey Pong
Merck & Co., Inc., Rahway, NJ 07065, USA
2 shared publications - Antonio Nicolucci
Center for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy
2 shared publications - Bertrand Cariou
Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du Thorax, Nantes, France
2 shared publications - Hirotaka Watada
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan
2 shared publications Iichiro Shimomura
10 Graduate School of Medicine Osaka University Osaka Japan
2 shared publications- Kamlesh Khunti
Diabetes Research Centre, College of Life Sciences University of Leicester Leicester UK
2 shared publications
Latest Publications
- Open Access
- 16 September 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (1) , 46-55
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
Aims: To describe glucose‐lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow‐up from the start of second‐line therapy. Materials and Methods: This data analysis from the 3‐year, observational DISCOVER study programme included 14 687 participants from 37 countries with T2D initiating second‐line glucose‐lowering therapy. Treatment and HbA1c data were collected at baseline (start of second‐line therapy) and at 6, 12, 24 and 36 months. Treatment regimen changes over follow‐up were analysed using the McNemar test, with carry‐forward imputation for intermediate missing values. Results: A total of 11 592 participants had treatment data at baseline and 36 months, and 11 882 had HbA1c data at baseline. At baseline and 36 months, respectively, rates of oral monotherapy use were 12.1% and 12.4% ( P = 0.22), rates of dual oral therapy use were 63.4% and 47.6% ( P < 0.0001), rates of ≥ triple oral therapy use were 17.5% and 25.4% ( P < 0.0001), and rates of injectable treatment use were 7.0% and 13.7% ( P < 0.0001). Use of injectable drugs was most common among participants with an HbA1c level ≥64 mmol/mol (≥8.0%). Overall, 42.9% of participants changed treatment during follow‐up. Mean HbA1c levels at baseline and 6 months were 67 mmol/mol (8.3%) and 55 mmol/mol (7.2%), respectively, remaining stable thereafter. Conclusions: Dual oral therapy was the most common treatment regimen at the start of second‐line treatment, and over half of the participants remained on the same treatment during follow‐up.
- 16 September 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (1) , 46-55
Open AccessTreatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
Aims: To describe glucose‐lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow‐up from the start of second‐line therapy. Materials and Methods: This data analysis from the 3‐year, observational DISCOVER study programme included 14 687 participants from 37 countries with T2D initiating second‐line glucose‐lowering therapy. Treatment and HbA1c data were collected at baseline (start of second‐line therapy) and at 6, 12, 24 and 36 months. Treatment regimen changes over follow‐up were analysed using the McNemar test, with carry‐forward imputation for intermediate missing values. Results: A total of 11 592 participants had treatment data at baseline and 36 months, and 11 882 had HbA1c data at baseline. At baseline and 36 months, respectively, rates of oral monotherapy use were 12.1% and 12.4% ( P = 0.22), rates of dual oral therapy use were 63.4% and 47.6% ( P < 0.0001), rates of ≥ triple oral therapy use were 17.5% and 25.4% ( P < 0.0001), and rates of injectable treatment use were 7.0% and 13.7% ( P < 0.0001). Use of injectable drugs was most common among participants with an HbA1c level ≥64 mmol/mol (≥8.0%). Overall, 42.9% of participants changed treatment during follow‐up. Mean HbA1c levels at baseline and 6 months were 67 mmol/mol (8.3%) and 55 mmol/mol (7.2%), respectively, remaining stable thereafter. Conclusions: Dual oral therapy was the most common treatment regimen at the start of second‐line treatment, and over half of the participants remained on the same treatment during follow‐up.
- Open Access
- 1 April 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (4) , S154-S155
POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
- 1 April 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (4) , S154-S155
Open AccessPOS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
- 23 July 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (12) , 2276-2286
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies
Aims To assess the efficacy and safety of ertugliflozin in older patients with type 2 diabetes (T2DM). Materials and methods This is a post hoc analysis of patients with T2DM aged <65 and ≥65 years who participated in randomized, double‐blind phase III studies of ertugliflozin. Efficacy was evaluated in a pooled analysis of three placebo‐controlled studies (ertugliflozin monotherapy and add‐on therapy). Safety was evaluated in a pooled analysis of seven placebo‐ and active‐controlled studies (including those used for efficacy). Least‐squares (LS) mean change from baseline was calculated for glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events (AEs). Results In participants aged <65 years, the placebo‐adjusted mean changes from baseline in HbA1c, BW and SBP with ertugliflozin 5 mg and 15 mg at Week 26 were: –0.9% and –1.0%; –1.9 kg and –1.8 kg; and –3.7 mmHg and –3.6 mmHg, respectively; in participants aged ≥65 years they were: –0.6% and –0.8%; –1.9 kg and –2.2 kg; and –2.7 mmHg and –3.4 mmHg, respectively. The incidences of AEs, serious AEs, discontinuations and deaths in participants aged <65 years and ≥65 years were generally similar across the treatment groups. In patients aged ≥65 years, the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non‐ertugliflozin. Conclusions Ertugliflozin improved glycaemic control, BW and SBP in younger and older individuals with T2DM and was generally well tolerated in both groups.
- 23 July 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (12) , 2276-2286
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies
Aims To assess the efficacy and safety of ertugliflozin in older patients with type 2 diabetes (T2DM). Materials and methods This is a post hoc analysis of patients with T2DM aged <65 and ≥65 years who participated in randomized, double‐blind phase III studies of ertugliflozin. Efficacy was evaluated in a pooled analysis of three placebo‐controlled studies (ertugliflozin monotherapy and add‐on therapy). Safety was evaluated in a pooled analysis of seven placebo‐ and active‐controlled studies (including those used for efficacy). Least‐squares (LS) mean change from baseline was calculated for glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events (AEs). Results In participants aged <65 years, the placebo‐adjusted mean changes from baseline in HbA1c, BW and SBP with ertugliflozin 5 mg and 15 mg at Week 26 were: –0.9% and –1.0%; –1.9 kg and –1.8 kg; and –3.7 mmHg and –3.6 mmHg, respectively; in participants aged ≥65 years they were: –0.6% and –0.8%; –1.9 kg and –2.2 kg; and –2.7 mmHg and –3.4 mmHg, respectively. The incidences of AEs, serious AEs, discontinuations and deaths in participants aged <65 years and ≥65 years were generally similar across the treatment groups. In patients aged ≥65 years, the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non‐ertugliflozin. Conclusions Ertugliflozin improved glycaemic control, BW and SBP in younger and older individuals with T2DM and was generally well tolerated in both groups.
- Open Access
- 1 May 2019
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 151, 20-32
Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study
- 1 May 2019
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 151, 20-32
Open AccessTreatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study
- 1 May 2018
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 202 (5-6) , 897-908
Le contrôle glycémique réduit-il les complications cardiovasculaires du diabète de type 2?
- 1 May 2018
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 202 (5-6) , 897-908
Le contrôle glycémique réduit-il les complications cardiovasculaires du diabète de type 2?
- Open Access
- 7 August 2017
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 2 (2) , 209-219
Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
Objectives Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods Data were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013. Results Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were €6506 ± 10,106 in the T2DM group as compared with €3668 ± 6954 in the control group. The cost difference between the two groups was €2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (€4153 ± 6170) and highest for those receiving insulin (€12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns. Conclusion Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over €8.5 billion. This estimate highlights the substantial economic burden of this condition on society.
- 7 August 2017
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 2 (2) , 209-219
Open AccessDirect Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
Objectives Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods Data were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013. Results Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were €6506 ± 10,106 in the T2DM group as compared with €3668 ± 6954 in the control group. The cost difference between the two groups was €2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (€4153 ± 6170) and highest for those receiving insulin (€12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns. Conclusion Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over €8.5 billion. This estimate highlights the substantial economic burden of this condition on society.
- 1 March 2016
- Published by Elsevier in Diabetes & Metabolism
- Vol. 42, A67
CA-117: L'hypoglycémie est-elle un risque modifiable chez les diabétiques de type 2 (DT2) ? Analyse des essais cliniques de l'insuline glargine 300U/mL (Gla-300) vs 100U/mL (Gla-100) en fonction du risque d'hypoglycémies à répétition
- 1 March 2016
- Published by Elsevier in Diabetes & Metabolism
- Vol. 42, A67
CA-117: L'hypoglycémie est-elle un risque modifiable chez les diabétiques de type 2 (DT2) ? Analyse des essais cliniques de l'insuline glargine 300U/mL (Gla-300) vs 100U/mL (Gla-100) en fonction du risque d'hypoglycémies à répétition
- Open Access
- 1 November 2014
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 28 (6) , 880-886
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
- 1 November 2014
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 28 (6) , 880-886
Open AccessLixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
- 6 June 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 97 (1) , 3-5
Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?
- 6 June 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 97 (1) , 3-5
Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?
- 1 January 2011
- Published by Touch Medical Media, Ltd. in US Endocrinology
- Vol. 07 (02)
Pioglitazone in Combination with Insulin—An Overview of Results from PROactive
Pioglitazone provides one of several add-on therapy options for patients with unsatisfactory glycemic control treated with insulin. Although pioglitazone has the beneficial feature of low hypoglycemia risk, it has an overlapping adverse event profile with insulin in terms of edema (with the potential to exacerbate heart failure) and weight gain, leading to possible concern over their use in combination. Fortunately, subgroup analyses from the Prospective pioglitazone clinical trial in macrovascular events (PROactive) have provided valuable insights into the efficacy and safety profile of pioglitazone in patients on established insulin therapy. Pioglitazone improved glycemic control and lipids, while enabling patients to reduce their insulin requirements. With the combination, edema and weight were predictable with no excess exacerbation of heart failure. Importantly, pioglitazone had a good macrovascular safety profile (with a trend toward benefit), consistent with the overall population. This article provides an overview of the results from the insulin-treated subgroup in PROactive and highlights some of the clinical implications for pioglitazone–insulin combination therapy.
- 1 January 2011
- Published by Touch Medical Media, Ltd. in US Endocrinology
- Vol. 07 (02)
Pioglitazone in Combination with Insulin—An Overview of Results from PROactive
Pioglitazone provides one of several add-on therapy options for patients with unsatisfactory glycemic control treated with insulin. Although pioglitazone has the beneficial feature of low hypoglycemia risk, it has an overlapping adverse event profile with insulin in terms of edema (with the potential to exacerbate heart failure) and weight gain, leading to possible concern over their use in combination. Fortunately, subgroup analyses from the Prospective pioglitazone clinical trial in macrovascular events (PROactive) have provided valuable insights into the efficacy and safety profile of pioglitazone in patients on established insulin therapy. Pioglitazone improved glycemic control and lipids, while enabling patients to reduce their insulin requirements. With the combination, edema and weight were predictable with no excess exacerbation of heart failure. Importantly, pioglitazone had a good macrovascular safety profile (with a trend toward benefit), consistent with the overall population. This article provides an overview of the results from the insulin-treated subgroup in PROactive and highlights some of the clinical implications for pioglitazone–insulin combination therapy.